Meta's GLP-1 Ad Rules: Who's Allowed to Run Them and Who Gets Banned

Can you advertise GLP-1 drugs on Facebook and Instagram at all?

Yes, but only inside a narrow authorization lane, not as a default advertiser privilege. Meta's Advertising Standards state plainly that promoting prescription drugs is not allowed without authorization from Meta, and that standard covers semaglutide, tirzepatide and every other GLP-1 brand name before creative even reaches ordinary ad review.

The gate has three parts: entity eligibility, certification, and geography. Meta restricts these ads to people 18 or older, and only in the United States, Canada and New Zealand — a narrower footprint than most advertisers assume. Running GLP-1 creative to a UK or Australian audience sits outside the policy entirely, authorization or not.

Which entity types qualify for Meta's prescription drug authorization?

Three entity types qualify: online pharmacies, telehealth providers, and pharmaceutical manufacturers. Meta treats them differently at the door. Online pharmacies and telehealth providers must hold active LegitScript certification before they can even apply; pharmaceutical manufacturers skip that requirement and instead apply directly for authorization through Meta's internal review.

A compounding pharmacy or med spa selling GLP-1 injections is not a listed entity type, and no version of the policy carves out a fourth lane for supplement companies, research-peptide sellers or direct-to-consumer clinics that don't hold a pharmacy or telehealth license. That's the entity restriction generic weight-loss compliance content rarely documents: the policy doesn't ban the drug class, it excludes everyone who isn't one of three named business models.

What role does LegitScript certification play on Meta?

LegitScript certification functions as Meta's outsourced credentialing check, not an optional trust badge. Online pharmacies and telehealth providers cannot begin the Meta authorization process without an active certification already in hand, and Meta does not offer a workaround for advertisers still mid-application.

The same credential does double duty across the ad ecosystem. Google requires LegitScript Healthcare Merchant Certification, or NABP accreditation, for online pharmacies, and LegitScript certification for telemedicine providers, in the US, Canada and Australia. TikTok takes a more fragmented route for supplements — country-by-country regulator proof such as Indonesia's BPOM or Thailand's FDA — rather than one recurring credential.

Google's own prescription drug reference list names semaglutide, tirzepatide, liraglutide, Ozempic, Wegovy, Mounjaro and Zepbound explicitly. That tells you the platforms aren't treating GLP-1 as a vague wellness category. They're keyword-matching brand and molecule names directly, which means generic weight-loss disclaimers won't dodge the certification requirement on any of the three.

How do weight-loss ad rules stack on top of drug rules?

Weight-loss rules don't replace the drug policy — they stack on it. An authorized GLP-1 advertiser still has to clear Health and Wellness, Personal Attributes and Unacceptable Business Practices on every single ad. Health and Wellness caps targeting at 18 and older for any dietary, health or weight-related product, bars statements of inferiority about physical appearance, and prohibits clickbait tactics such as sensational language with exaggerated or extreme claims.

Personal Attributes adds a second-person trap that catches advertisers who never think of themselves as making a health claim. Meta's own compliance example contrasts 'Depression counseling,' which is fine, against 'Depression getting you down? Get help now,' which is banned — the same logic covers 'your diabetes' or 'tired of your weight' copy, the exact pattern addressed in the 'you' rule that governs personal attributes in Meta ads. Claims that a product cures or eliminates incurable conditions such as diabetes are barred outright, even when attributed to a health professional.

Unacceptable Business Practices closes the loop by banning deceptive or exaggerated claims about health-related benefits, and Meta names health and weight-loss products specifically as a frequent violation category alongside investment schemes. An account can be fully authorized under Drugs and Pharmaceuticals and still get an ad rejected, or the asset restricted, for tripping one of these adjacent layers.

Why did 35 state attorneys general pressure Meta over GLP-1 ads in late 2025?

The specific figure — a coalition of 35 state attorneys general sending Meta a joint letter in late 2025 — isn't confirmed against a primary source checked for this page, so treat that exact count as needing verification rather than settled fact. What's documented is a parallel pattern of individual state enforcement against GLP-1 and peptide marketing severe enough to plausibly produce that kind of coalition pressure.

Alabama's attorney general sued Aurora IV and Wellness in November 2025 under the state's Deceptive Trade Practices Act for advertising pharmaceutical-grade tirzepatide and semaglutide while actually injecting patients with research-labeled material. The case ended in permanent closure, roughly $24,000 in damages and penalties, and surrender of a nursing license. Connecticut's attorney general separately sued a raw-powder distributor in May 2025 and sent corporate-practice cease-and-desist letters to three weight-loss businesses that December.

State AGs pursuing individual cases and a coalition letter pressuring a platform are two different mechanisms, and this page can't verify the second happened at the scale claimed. What's safe to say: state-level GLP-1 enforcement escalated sharply through 2025 into 2026, and platform policy tightened on a similar timeline — Meta's expanding advertiser verification program and its February 2026 lawsuits against healthcare-related scam advertisers both sit inside that same window.

What creative patterns get GLP-1-adjacent accounts banned?

The patterns that get GLP-1-adjacent accounts banned usually aren't the disclosed drug claims — entity and certification review catches those. It's the workarounds advertisers build to dodge that review. Meta's Account Integrity standard, which absorbed what used to be a standalone circumvention policy, prohibits accounts created or repurposed to evade a previous account or entity removal, and applies at the entity level, meaning a restriction can reach every Page and ad account tied to that business, not just the flagged one.

Deepfake and synthetic-doctor creative is a documented enforcement target, not a hypothetical risk. Meta's February 2026 lawsuits named deepfakes of a physician used to advertise unapproved healthcare products, alongside altered celebrity images promoting fraudulent healthcare offers. The same AI-generated-spokesperson pattern shows up constantly in weight-loss creative, which is a large part of why Meta rejects AI avatar ads in this category even when the underlying offer is legitimate.

Before-and-after transformation imagery isn't banned outright for weight-related products, but it draws different scrutiny than general cosmetic before/after content, and enough shifted in 2026 that older creative libraries are worth auditing against the current before-and-after photo policy. Pairing dramatic transformation photos with unverified GLP-1 branding stacks a Health and Wellness violation on top of an Unacceptable Business Practices flag on the same asset.

None of this explains why a feed scroll still turns up an obviously noncompliant GLP-1 ad running beside a freshly banned account making the identical claim. It isn't that the surviving account 'warmed up' its spend — no platform documents spend history buying lighter review, and Meta's own process states review relies primarily on automated tools applied to every ad, live or not. The real answer is enforcement variance, covered directly in why competitors seem to run ads that would get you banned.

Can supplement offers reference GLP-1 or Ozempic in Meta ads?

Not safely, and doing it anyway is the fastest way to convert a supplement account into a drug-claim account. Under FDA's disclaimer rule at 21 CFR 101.93(g)(2)(iv)(B), naming an ingredient regulated by FDA as a drug and well known to consumers for treating a disease is itself evidence of an implied disease claim — so 'works like Ozempic' or 'natural GLP-1 alternative' hands FDA the exact evidence it needs to reclassify the product, independent of whatever Meta does.

Meta's Health and Wellness and Personal Attributes rules add a second, faster failure mode on top. 'Natural Ozempic alternative' reads as both a comparative health claim and an implied statement about the viewer's body. Supplement offers running through affiliate networks carry an extra layer worth checking — the network-side rules are covered in ClickBank's ad compliance requirements, which restrict comparative drug-brand claims independent of what Meta or FDA enforce.

Google draws the same line from the advertiser side: its Unapproved substances policy bans products that imply they are as effective as prescription drugs outright, regardless of any claims of legality — meaning a disclaimer doesn't cure the claim there either. FTC guidance makes the identical point about disclaimers generally: in one enforcement example, an app claiming to treat acne carried a 'not intended for treatment' disclaimer that FTC called directly contradictory and ineffective against the claim it was supposedly disclaiming.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

When the topic touches health claims, platform policy, or GLP-1 market research, validate the observable campaign signals against primary references such as FDA human drug compounding, FTC health claims guidance, and Meta advertising standards. Daily Intel adds the proprietary direct-response layer by mapping how those rules show up in active VSLs, Meta creatives, funnels, transcripts, UTMs, and checkout paths.

For deeper evaluation, continue through Nutra niche intelligence directory, The Claim Ceiling by Condition: How High Each Niche Lets You Go, The Hardest Nutra Niches to Advertise, Condition by Condition, Which Nutra Niches Actually Convert on Cold Traffic, Nutra Niches a Beginner Should Not Start In, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.